# Oragenics Inc: Form 10-Q for the period ended Mar 31, 2020

- Company: [Oragenics Inc](/companies/ogen.md) (CIK 1174940)
- Form: 10-Q
- Filed: 2020-05-15
- Accepted by EDGAR: May 15, 2020, 16:01 ET
- Period: 2020-03-31
- Accession: 0001493152-20-009088
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1174940/000149315220009088/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1174940/000149315220009088/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2020-01-01 to 2020-03-31 | $3.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | −$5.2m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | −$5.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | −$0.11 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | −$3.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2020-03-31 | $14.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-03-31 | $14.7m | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $15.6m | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $2.0m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2020-03-31 | $12.9m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1174940/000149315220009088/form10-q.htm

Filed May 15, 2020.
Source: SEC EDGAR, the filing index for accession 0001493152-20-009088. Last ingested by Listed: Nov 13, 2026, 16:40 ET. No prices; not investment advice.
